{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:05:29Z","timestamp":1776812729345,"version":"3.51.2"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"suppl_3","license":[{"start":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T00:00:00Z","timestamp":1543363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01AI119954"],"award-info":[{"award-number":["U01AI119954"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11,28]]},"DOI":"10.1093\/cid\/ciy609","type":"journal-article","created":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T03:41:13Z","timestamp":1532662873000},"page":"S317-S326","source":"Crossref","is-referenced-by-count":37,"title":["Ethionamide Pharmacokinetics\/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis"],"prefix":"10.1093","volume":"67","author":[{"given":"Devyani","family":"Deshpande","sequence":"first","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jotam G","family":"Pasipanodya","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stellah G","family":"Mpagama","sequence":"additional","affiliation":[{"name":"Kibong\u2019oto Infectious Diseases Hospital, Sanya Juu, Tanzania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shashikant","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Bendet","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thearith","family":"Koeuth","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooi S","family":"Lee","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott K","family":"Heysell","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and International Health, University of Virginia, Charlottesville"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7592-8012","authenticated-orcid":false,"given":"Tawanda","family":"Gumbo","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,11,28]]},"reference":[{"key":"key\n\t\t\t\t2019012510072177600_CIT0001","doi-asserted-by":"crossref","first-page":"1602308","DOI":"10.1183\/13993003.02308-2016","article-title":"World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update","volume":"49","author":"Falzon","year":"2017","journal-title":"Eur Respir J"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0002","doi-asserted-by":"crossref","first-page":"e0123655","DOI":"10.1371\/journal.pone.0123655","article-title":"High frequency of resistance, lack of clinical benefit, and poor outcomes in capreomycin treated South African patients with extensively drug-resistant tuberculosis","volume":"10","author":"Pietersen","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0003","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1128\/AAC.00962-16","article-title":"Artificial intelligence and amikacin exposures predictive of outcomes in multidrug-resistant tuberculosis patients","volume":"60","author":"Modongo","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0004","doi-asserted-by":"crossref","first-page":"5922","DOI":"10.1128\/AAC.00961-16","article-title":"Amikacin optimal exposure targets in the hollow-fiber system model of tuberculosis","volume":"60","author":"Srivastava","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0005","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1093\/cid\/civ425","article-title":"Systematic analysis of hollow fiber model of tuberculosis experiments","volume":"61","author":"Pasipanodya","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0006","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/cid\/civ484","article-title":"Hollow fiber system model for tuberculosis: the European Medicines Agency experience","volume":"61","author":"Cavaleri","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0007","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1093\/cid\/civ460","article-title":"The hollow fiber system model in the nonclinical evaluation of antituberculosis drug regimens","volume":"61","author":"Chilukuri","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0008","article-title":"Qualification opinion. In-vitro hollow fiber system model of tuberculosis (HSF-TB)","volume-title":"Agency EM","author":"EMA","year":"2015"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0009","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.8284673","article-title":"inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis","volume":"263","author":"Banerjee","year":"1994","journal-title":"Science"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0010","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1128\/AAC.00077-13","article-title":"Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes","volume":"57","author":"Huyen","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0011","first-page":"344","article-title":"inhA promoter mutations: a gateway to extensively drug-resistant tuberculosis in South Africa","volume":"15","author":"M\u00fcller","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0012","doi-asserted-by":"crossref","first-page":"e0135003","DOI":"10.1371\/journal.pone.0135003","article-title":"High prevalence of inhA promoter mutations among patients with drug-resistant tuberculosis in KwaZulu-Natal, South Africa","volume":"10","author":"Niehaus","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0013","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1128\/AAC.05546-11","article-title":"The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance","volume":"56","author":"Schmalstieg","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0014","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1086\/651377","article-title":"Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol","volume":"201","author":"Srivastava","year":"2010","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0015","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1111\/j.1365-2958.2005.04510.x","article-title":"The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol","volume":"55","author":"Colangeli","year":"2005","journal-title":"Mol Microbiol"},{"issue":"Suppl 3","key":"key\n\t\t\t\t2019012510072177600_CIT0016","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1093\/cid\/ciy611","article-title":"Gatifloxacin pharmacokinetics\/pharmacodynamics-based optimal dosing for pulmonary and meningeal multidrug-resistant tuberculosis","volume":"67","author":"Deshpande","year":"2018","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0017","doi-asserted-by":"crossref","first-page":"e1701102","DOI":"10.1126\/sciadv.1701102","article-title":"Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis","volume":"3","author":"Deshpande","year":"2017","journal-title":"Sci Adv"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0018","doi-asserted-by":"crossref","first-page":"e02232","DOI":"10.1128\/AAC.02232-17","article-title":"On the antibacterial and sterilizing effect of benzylpenicillin in tuberculosis","volume":"62","author":"Deshpande","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 3","key":"key\n\t\t\t\t2019012510072177600_CIT0019","doi-asserted-by":"crossref","first-page":"S267","DOI":"10.1093\/cid\/ciy608","article-title":"An introduction to pharmacokinetics\/pharmacodynamics methods and scientific evidence base for dosing of second line tuberculosis drugs","volume":"67","author":"Gumbo","year":"2018","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0020","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1086\/424849","article-title":"Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling","volume":"190","author":"Gumbo","year":"2004","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0021","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1093\/infdis\/jiv183","article-title":"Nonclinical models for antituberculosis drug development: a landscape analysis","volume":"211","author":"Gumbo","year":"2015","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0022","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1128\/AAC.00185-07","article-title":"Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0023","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/infdis\/jir658","article-title":"Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability","volume":"204","author":"Srivastava","year":"2011","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0024","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1128\/AAC.45.3.810-814.2001","article-title":"Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids","volume":"45","author":"Auclair","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0025","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1093\/cid\/ciw474","article-title":"A faropenem, linezolid, and moxifloxacin regimen for both drug-susceptible and multidrug-resistant tuberculosis in children: FLAME path on the milky way","volume":"63","author":"Deshpande","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0026","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00284-006-0135-1","article-title":"Nucleotide polymorphism associated with ethambutol resistance in clinical isolates of Mycobacterium tuberculosis","volume":"53","author":"Srivastava","year":"2006","journal-title":"Curr Microbiol"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0027","doi-asserted-by":"crossref","first-page":"e00751","DOI":"10.1128\/AAC.00751-17","article-title":"Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis","volume":"61","author":"Srivastava","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0028","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1054\/tube.2002.0330","article-title":"Population pharmacokinetics of ethionamide in patients with tuberculosis","volume":"82","author":"Zhu","year":"2002","journal-title":"Tuberculosis"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0029","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0022-3476(89)80862-5","article-title":"Cerebrospinal fluid concentrations of ethionamide in children with tuberculous meningitis","volume":"115","author":"Donald","year":"1989","journal-title":"J Pediatr"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0030","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0140-6736(62)91602-1","article-title":"Ethionamide: its passage into the cerebrospinal fluid in man","volume":"1","author":"Hughes","year":"1962","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0031","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1128\/AAC.44.5.1337-1341.2000","article-title":"Effects of AIDS and gender on steady-state plasma and intrapulmonary ethionamide concentrations","volume":"44","author":"Conte","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0032","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/jac\/dkh120","article-title":"Use of MGIT 960 for rapid quantitative measurement of the susceptibility of Mycobacterium tuberculosis complex to ciprofloxacin and ethionamide","volume":"53","author":"Huang","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0033","doi-asserted-by":"crossref","first-page":"e0170663","DOI":"10.1371\/journal.pone.0170663","article-title":"Determination of plasma concentrations of levofloxacin by high performance liquid chromatography for use at a multidrug-resistant tuberculosis hospital in Tanzania","volume":"12","author":"Ebers","year":"2017","journal-title":"PLoS One"},{"issue":"Suppl 3","key":"key\n\t\t\t\t2019012510072177600_CIT0034","first-page":"S312","article-title":"Levofloxacin pharmacokinetics-pharmacodynamics, dosing, susceptibility breakpoints, and artificial intelligence in the treatment of multidrug-resistant tuberculosis","volume":"67","author":"Deshpande","year":"2018","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0035","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1128\/AAC.03931-14","article-title":"Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis","volume":"59","author":"Chigutsa","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0036","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1093\/cid\/cix158","article-title":"Concentration-dependent antagonism and culture conversion in pulmonary tuberculosis","volume":"64","author":"Rockwood","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1214\/aos\/1176347963","article-title":"Multivariate adaptive regression splines","volume":"19","author":"Friedman","year":"1991","journal-title":"Ann Statist"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0038","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/096228029500400303","article-title":"An introduction to multivariate adaptive regression splines","volume":"4","author":"Friedman","year":"1995","journal-title":"Stat Methods Med Res"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0039","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ebiom.2016.07.031","article-title":"The non-linear child: ontogeny, isoniazid concentration, and NAT2 genotype modulate enzyme reaction kinetics and metabolism","volume":"11","author":"Rogers","year":"2016","journal-title":"EBioMedicine"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0040","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1093\/infdis\/jiu610","article-title":"Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia","volume":"211","author":"Gumbo","year":"2015","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0041","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1128\/AAC.37.3.483","article-title":"Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis","volume":"37","author":"Drusano","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0042","doi-asserted-by":"crossref","first-page":"7104","DOI":"10.1128\/AAC.01117-15","article-title":"Sensititre MYCOTB MIC plate compared to Bactec MGIT 960 for first- and second-line antituberculosis drug susceptibility testing in Tanzania: a call to operationalize MICs","volume":"59","author":"Heysell","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0043","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1128\/AAC.01474-09","article-title":"New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic\/pharmacodynamic science and population pharmacokinetic variability","volume":"54","author":"Gumbo","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0044","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1128\/AAC.45.1.13-22.2001","article-title":"Use of preclinical data for selection of a phase II\/III dose for evernimicin and identification of a preclinical MIC breakpoint","volume":"45","author":"Drusano","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 3","key":"key\n\t\t\t\t2019012510072177600_CIT0045","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1093\/cid\/ciy618","article-title":"D-cycloserine pharmacokinetics-pharmacodynamics, susceptibility, and dosing implications in multidrug-resistant tuberculosis: a Faustian deal","volume":"67","author":"Deshpande","year":"2018","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0046","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/ng.2675","article-title":"Biological variability and the emergence of multidrug-resistant tuberculosis","volume":"45","author":"Gumbo","year":"2013","journal-title":"Nat Genet"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0047","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.coph.2011.07.001","article-title":"A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs","volume":"11","author":"Pasipanodya","year":"2011","journal-title":"Curr Opin Pharmacol"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0048","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0165-6147(00)89020-3","article-title":"Agonist-receptor efficacy. I: mechanisms of efficacy and receptor promiscuity","volume":"16","author":"Kenakin","year":"1995","journal-title":"Trends Pharmacol Sci"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0049","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/462167a","article-title":"Drug discovery: predicting promiscuity","volume":"462","author":"Hopkins","year":"2009","journal-title":"Nature"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0050","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1021\/ci300196g","article-title":"Structural insights into the molecular basis of the ligand promiscuity","volume":"52","author":"Sturm","year":"2012","journal-title":"J Chem Inf Model"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0051","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.chembiol.2011.12.012","article-title":"Systems biology and systems chemistry: new directions for drug discovery","volume":"19","author":"Brown","year":"2012","journal-title":"Chem Biol"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0052","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.tibs.2013.11.002","article-title":"Towards understanding promiscuity in multidrug efflux pumps","volume":"39","author":"Wong","year":"2014","journal-title":"Trends Biochem Sci"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0053","doi-asserted-by":"crossref","first-page":"6837","DOI":"10.1128\/AAC.03285-14","article-title":"Mutations in the embC-embA intergenic region contribute to Mycobacterium tuberculosis resistance to ethambutol","volume":"58","author":"Cui","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012510072177600_CIT0054","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/MD.0b013e3181df9070","article-title":"Meningeal tuberculosis: high long-term mortality despite standard therapy","volume":"89","author":"Shaw","year":"2010","journal-title":"Medicine"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/67\/suppl_3\/S317\/26826241\/ciy609.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T08:13:23Z","timestamp":1661674403000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/67\/suppl_3\/S317\/5212755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,28]]},"references-count":54,"journal-issue":{"issue":"suppl_3","published-online":{"date-parts":[[2018,11,28]]},"published-print":{"date-parts":[[2018,11,28]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy609","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,12,15]]},"published":{"date-parts":[[2018,11,28]]}}}